Atherosclerosis and infection?

Czech version

Authors: K. Zeman
Authors‘ workplace: I. interní kardioangiologická klinika Lékařské fakulty MU a FN u sv. Anny, Brno, přednosta prof. MUDr. Jiří Vítovec, CSc., FESC
Published in: Vnitř Lék 2006; 52(9): 823-826
Category: Short Communication

Overview

Atherosclerosis is guided by chronicle inflammation process. In the last decades of the 20th century, studies considering infection another possible risk factor of atherosclerosis development were written. Helicobacter pylori, Porphyroma gingivalis, some viruses but most frequently Chlamydia pneumonie are infection agens mentioned in these studies. Some of them emphasize also combined infections caused by more pathogenic factors having influence on vascular inflammation. Serological, epidemiological, histological and imunological studies show the pathogenic influence of acute or chronic infections. Many studies selected makrolid antibiotics as treatment in patients with ischaemic heart disease. However, existing experience with antibiotics did not bring clear results. These studies have mentioned the fact antibiotics have not been indicated as treatment in patients with acute or chronic vascular system infliction by atherosclerosis. Since the experimental and clinical research of influence of inflammations on the development of atherosclerosis moved forward a lot, no exact evidence of this complicated pathogenic mechanism was given. It will obviously take some time to confirm whether the relation between infections and artherosclerosis is causal, i.e. initiating the pathogenic process, accelerating it or keeping it alive.

Key words:
atherosclerosis – infection

Sources

1. Šimon J. K nově objeveným rizikovým faktorům aterosklerózy a ischemické choroby srdeční. Cor Vasa 1998; 40: 323-324.

2. Saikku P, Leuinomeni M, Mattila K et al. Serological evidence of an association of a novel Chlamydia TWAR with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; 2: 983-985.

3. Saikku P, Leinonen M, Tenkanen L Chronic Chlamydia pneumoniae infection as a Risk factor for Coronary Heart disease in the Helsinki Heart Study. Ann Int Med 1992; 116: 273-278.

4. Renvert S, Ohlsson S, Persson S et al. Analysis of periodontal risk profiles in adults with or without a history of myocardial infarction. J Clin Periodontol 2004; 31: 19-24.

5. Dodet B. Infection and Atherosclerosis. Amer Heart J 1999; 138: 417-418.

6. Fong IW Emerging relation between infections disease and coronary artery disease and atherosclerosis. Canadian Med Assoc J 2000; 163: 49-56.

7. Zeman K, Pospíšil L, Diblíková I et al. Chlamydia pneumoniae a infarkt myokardu. Vnitř Lék 2001; 47: 852-855.

8. Medková Z, Kalousek I, Jarčuška P. Chlamydiové infekce. Praha: Triton 2001.

9. Gupta S, Camm AJ. Chlamydia pneumoniae and coronary heart disease. BMJ 1997; 314: 1778-1779.

10. Wong YK, Gallagher PJ, Ward ME. Chlamydia pneumonaie and atherosclerosis. Heart 1999; 81: 232-238.

11. Zhu J, Nieto FJ, Horne BD et al. Prospective study of pathogen burden and risk of myocardial infarction or death. Circulation 2001; 103: 45-51.

12. Ben-Yaakov M, Eshel G, Zaksonski L et al. Prevalence of antibodies to Chlamydia pneumoniae in an Israeli population without clinical evidence of respiratory infection. J Clin Pathol 2002; 55: 355-358.

13. Zhu J, Nieto FJ, Home BD et al. Prospective study of pathogen burden and risk of myocardial infarction or death. Circulation 2001; 103: 45-51.

14. Mahdi OS, Horne BD, Mullen K et al. Serum immunoglobulin G antibodies to chlamydial heat shock protein 60 but not to human and bacterial homologs are associated with coronary disease. Circulation 2002; 106: 1659-1663.

15. Pospíšil L, Čanderle J, Zeman K et al. Serologické vyšetření u aterosklerózy a jejich cévních komplikací. Epidemiol Mikrobiol Immunol 2003; 52: 142-146.

16. Danesh J, Whincup P, Walker M et al. Chlamydia pneumoniae IgG titres and coronary heart disease prospective study and meta-analysis. BMJ 2000; 321: 208-213.

17. Pospíšil L, Čanderle J, Štroblová H et al. Protilátky proti proteinu tepelného šoku a dalším antigenům chlamydií u některých chorob ve srovnání s jejich výskytem u dárců krve. Čas Lék Čes 2003; 142: 661-664.

18. Štercl J. Imunitní systém a jeho fyziologické funkce. Praha: Čes imunolog. spol. 1993: 1-480.

19. Ošťádal P. Úloha zánětu v patogenezi akutních forem ischemické choroby srdeční. Cor Vasa 1997; 39: 231-234.

20. Meniconi A, Noll G, Litscher TF Is arteriosclerosis an infectious disease? Schweiz Rundsch Med Prax 1998; 87: 64-74.

21. Stemme S, Faber B, Holm J et al. T lymphocytes from human atherosclerotic plaques recognize low density lipoprotein. Proc Natl Acad Sci USA 1995; 92: 3893-3897.

22. Haverkate F, Thomptson SG, Pyke SDM et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997; 349: 462-466.

23. Gabay C, Kushner I Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-454.

24. Gupta S, Leatham EW, Carington D et al. Elevated Chlamydia pneumoniae antibodies, cardiovascular events and azithromycin in male survivors of acute myocardial infarction. Circulation 1997; 96: 404-407.

25. Gurfinkel E, Bozovich G, Beck E et al. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes: The final report of the ROXIS Study. Eur Heart J 1999; 20: 121-127.

26. Neuman FJ, Kastrati A, Miethke T et al. Treatment of Clamydia pneumoniae infection with roxithromycin and efect on neointima proliferation after coronary stent placement (ISAR-3): a randomised double-blind, placebo-controlled trial. Lancet 2001; 357: 2085-2089.

27. O´Conor, CM, Dunne MW, Pfeffer MA et al. Azithromycin for the secondary prevention of coronary heart disease events. The WISARD study: a randomized controlled trial. JAMA 2003; 290: 1359-1466.

28. Pravastatin or Atrovastatin Evaluatio Infection Therapy - Thrombolysis In Myocardial Infarction (PROVE IT-TIMI 22). Ústní sdělení na kongresu Evropské kardiologické společnosti (Europien Society of Cardiology) Cannon CP (Boston, USA) 30. 7. 2004. Mnichov.

29. Grayston JT, Kronmal RA, Jackson LA et al. Azithromycin for the Secondary Prevention of Coronary Events (ACES). N Engl J Med 2005; 346: 1637-1645.

30. Espinola-Klein Ch, Rupprecht HJ, Blankenberg S et al. Impact of Infectious Burde on Extent and Long-Term Prognosis of Aterosclerosis. Circulation 2002; 105: 14-21.

31. Stone AF, Mendall MA, Kaski JC et al. Effect of Treatment for Chlamydia pneumoniae and Helicobacter pylori on Markers of Inflammation and Cardiac Events in Patients With Acute Coronary Syndromes. South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STATIMA). Circulation 2002; 106: 1219-1223.

32. Chi H, Messas E, Levine RA et al. Interleukin-1 Receptor Signaling Mediates Atherosclerosis Associated With Bacterial Exposure and or a High-Fat Diet in s Murine Apolipoprotein E Heterozygote Model. Circulation 2004; 21: 1678-1685.

33. Tiong AY, Brieger D. Inflamation and coronary artery disease. Am Heart J 2005; 150: 11-18.